Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

Role of DW-MRI in monitoring therapy in head and neck squamous cell carcinoma

Joint Event on 5th Edition of International Conference on Clinical Oncology and Molecular Diagnostics & 5th World Congress on Medical Imaging & Clinical Research
June 17-18, 2019 Rome, Italy

Manal F Abu Samra

Minia University, Egypt

Scientific Tracks Abstracts: Arch Cancer Res

Abstract:

Aim: To evaluate the role of DW-MRI and ADC value in monitoring therapy of head and neck squamous cell carcinoma.

Patients & Methods: 40 patients with head and neck squamous cell carcinoma, age ranged from 40 to 68 years, 30 patients were male while 10 were female. Pre-treatment examinations included contrast-enhanced CT, endoscopic biopsy and Conventional MRI. Pre-treatment includes 1st DW-MRI imaging within 10 days before treatment (ADC1), 2nd imaging 3 weeks after start of treatment (ADC2) and 3rd after 6 to 8 weeks from end of treatment.

Results: Significant changes between mean ADC value of 40 primary lesions and 22 metastatic LNs, noted at ADC1 and ADC2, indicating high ability of DW-MRI to detect early changes occurs after beginning of treatment. Relationship between pretreatment ADC value and prediction of early treatment response revealed 76.9% sensitivity, 71.4% specificity, 83.3% PPV and 62.5% NPV. ROC curve for fractional ADC value change (ADC2-ADC1) from 40 lesions primary tumors provided best discriminatory accuracy (AUC=0.85±0.09) in distinguishing between responders and non-responders with 92.3% sensitivity, 85.7% specificity, 92.9% PPV and 85.7% NPV.

Conclusion: Intra treatment ADC value can be used as a marker for prediction and monitoring therapy response for HNSCC.

Biography :

E-mail:

manal_abusamra@ymail.com